Business Description
IO Biotech Inc
NAICS : 325412
SIC : 2834
ISIN : US4497781090
Description
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 50.94 | |||||
| Equity-to-Asset | 0.9 | |||||
| Debt-to-Equity | 0.02 | |||||
| Debt-to-EBITDA | -0.03 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -23.1 | |||||
| 3-Year EPS without NRI Growth Rate | -23.6 | |||||
| 3-Year FCF Growth Rate | -24.3 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 15.09 | |||||
| 9-Day RSI | 22.18 | |||||
| 14-Day RSI | 28.04 | |||||
| 6-1 Month Momentum % | 24.79 | |||||
| 12-1 Month Momentum % | -29.81 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 11.24 | |||||
| Quick Ratio | 11.24 | |||||
| Cash Ratio | 10.68 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -78.7 | |||||
| Shareholder Yield % | 0.2 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -69.69 | |||||
| ROA % | -62.69 | |||||
| ROIC % | -1179.83 | |||||
| ROC (Joel Greenblatt) % | -2784.43 | |||||
| ROCE % | -68.85 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 0.68 | |||||
| Price-to-Tangible-Book | 0.68 | |||||
| EV-to-EBIT | 0.42 | |||||
| EV-to-Forward-EBIT | -0.02 | |||||
| EV-to-EBITDA | 0.43 | |||||
| EV-to-FCF | 0.46 | |||||
| Price-to-Net-Current-Asset-Value | 0.7 | |||||
| Price-to-Net-Cash | 0.74 | |||||
| Earnings Yield (Greenblatt) % | 238.1 | |||||
| FCF Yield % | -105.25 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IOBT
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
IO Biotech Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -1.867 | ||
| Beta | 0 | ||
| Volatility % | 93 | ||
| 14-Day RSI | 28.04 | ||
| 14-Day ATR ($) | 0.129332 | ||
| 20-Day SMA ($) | 1.383 | ||
| 12-1 Month Momentum % | -29.81 | ||
| 52-Week Range ($) | 0.8163 - 2.215 | ||
| Shares Outstanding (Mil) | 65.88 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
IO Biotech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
IO Biotech Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
IO Biotech Inc Frequently Asked Questions
What is IO Biotech Inc(IOBT)'s stock price today?
The current price of IOBT is $1.19. The 52 week high of IOBT is $2.22 and 52 week low is $0.82.
When is next earnings date of IO Biotech Inc(IOBT)?
The next earnings date of IO Biotech Inc(IOBT) is 2024-08-09 Est..
Does IO Biotech Inc(IOBT) pay dividends? If so, how much?
IO Biotech Inc(IOBT) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers